Historical record - last NADAC effective date: 11/19/2014
This NDC is on FDA's drug shortage list (posted Mar 13, 2023)
Reported reason: Other
Product Information
METHOTREXATE 1 GRAM/40 ML VIAL is a generic product labeled by Accord Healthcare Inc., priced at $0.6450 per ML under NDC 16729027735. Its NADAC has been published 85 times since May 7, 2014.
FDA first approved this application on Apr 30, 2007. Its Orange Book therapeutic-equivalence code is AP.
Strength
25 mg/mL
Manufacturer
Accord Healthcare Inc.NDC
16729027735
Classification
Generic
Dosage Form
INJECTION
Route
INTRA-ARTERIAL; INTRAMUSCULAR; INTRATHECAL; INTRAVENOUS
Effective Date
11/19/2014
Active Ingredients
METHOTREXATEApproval Type
Generic (ANDA)
FDA Application
ANDA040716FDA Approved
4/30/2007
TE Code
AP
On Market Since
3/7/2014
Pharmacological Classes
Price Statistics
The NADAC for METHOTREXATE 1 GRAM/40 ML VIAL has been published 85 times since May 7, 2014, and over the history we have for it it has declined 29.5%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.6450 per ML |
|---|---|
| All-time high | $0.9146 (Nov 12, 2014) |
| All-time low | $0.6450 (Nov 19, 2014) |
| Median price | $0.6450 |
| Average price | $0.7338 |
| Largest weekly change | -29.5% (Nov 19, 2014) |
| Weeks tracked | 85 |
| Tracking since | May 7, 2014 |
1W
N/A
1M
N/A
3M
N/A
6M
N/A
1Y
N/A
3Y
N/A
5Y
N/A
All
-29.5%
Last surveyed Dec 16, 2015 — this NDC no longer appears in the current weekly NADAC file.
Generic Alternatives
The matcher finds 3 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Accord Healthcare Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Methotrexate market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Folate Analog Metabolic Inhibitor class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of METHOTREXATE 1 GRAM/40 ML VIAL?
The current National Average Drug Acquisition Cost (NADAC) for METHOTREXATE 1 GRAM/40 ML VIAL, manufactured by Accord Healthcare Inc., is $0.6450 per ML (NDC 16729027735), effective Dec 16, 2015.
How has the price of METHOTREXATE 1 GRAM/40 ML VIAL changed over time?
Over the history we have for it, the NADAC for METHOTREXATE 1 GRAM/40 ML VIAL has declined 29.5%. It has been tracked across 85 weekly CMS publications since May 7, 2014.
What are the highest and lowest recorded NADAC prices for METHOTREXATE 1 GRAM/40 ML VIAL?
Since May 7, 2014, the NADAC for METHOTREXATE 1 GRAM/40 ML VIAL has ranged from a low of $0.6450 (Nov 19, 2014) to a high of $0.9146 (Nov 12, 2014), with a median of $0.6450 per ML.
Are there cheaper alternatives to METHOTREXATE 1 GRAM/40 ML VIAL?
3 manufacturers publish a NADAC-priced product with the same active ingredient and strength as METHOTREXATE 1 GRAM/40 ML VIAL in a comparable dosage form, but none are currently priced below it.
Who manufactures METHOTREXATE 1 GRAM/40 ML VIAL?
METHOTREXATE 1 GRAM/40 ML VIAL (NDC 16729027735) is labeled by Accord Healthcare Inc., and CMS classifies it as a generic product.
Is METHOTREXATE 1 GRAM/40 ML VIAL in shortage?
Yes — NDC 16729027735 is currently listed in FDA's drug shortage database (posted Mar 13, 2023). Reported reason: Other.